Really?

Disclaimer: This is a comprehensive overview based on publicly available scientific information and is not a peer-reviewed research paper. It should not be used as a substitute for professional medical advice. For academic or medical purposes, you must independently verify all sources and information.

The Scientific Consensus on Ivermectin for COVID-19

Introduction

The search for effective treatments during the COVID-19 pandemic led to the investigation of numerous existing drugs for their potential to combat the SARS-CoV-2 virus.¹ Among them, the antiparasitic drug ivermectin received significant attention.² While initial laboratory studies and small-scale trials generated a surge of public interest and political promotion, a robust scientific consensus has emerged. This overview summarizes the findings of major clinical trials and the positions of leading global health organizations, confirming that ivermectin is not an effective treatment for COVID-19.

Initial Findings vs. Large-Scale Clinical Trials

The early enthusiasm for ivermectin stemmed from in vitro (test-tube) studies. One study, for instance, found that high concentrations of ivermectin could inhibit SARS-CoV-2 replication in a cell culture.³ However, to achieve a similar concentration in human lung tissue would require doses far higher than those considered safe for humans, leading to potential toxicity.⁴ This is a crucial distinction: what works in a lab setting often does not translate to a safe and effective treatment in a living organism.

Following these initial findings, a number of smaller, often poorly designed clinical trials were conducted. Some of these trials suggested a potential benefit, which contributed to the drug’s promotion by certain groups.⁵ However, many of these studies had significant methodological flaws, including a lack of proper blinding, small sample sizes, or missing data, which made their results unreliable.⁶

To address these shortcomings and provide a definitive answer, several large, well-designed randomized controlled trials (RCTs) were launched globally. These trials are considered the gold standard for medical research. Key studies, such as the PRINCIPLE Trial in the UK and the ACTIV-6 Trial in the US, enrolled thousands of participants with mild to moderate COVID-19 to test ivermectin against a placebo or standard care.⁷

The findings from these rigorous trials were consistent: ivermectin did not reduce the risk of COVID-19-related hospitalizations or deaths.⁸ While some trials noted a minor, statistically insignificant reduction in recovery time, this was not considered a “clinically meaningful” benefit that would justify its widespread use.⁹

Official Recommendations from Global Health Organizations

The overwhelming evidence from these large trials led major health organizations to issue strong recommendations against using ivermectin to treat COVID-19.

The Cochrane Library: A global non-profit that produces systematic reviews of medical research, the Cochrane Library found no credible evidence to support the use of ivermectin for preventing or treating COVID-19.¹⁰ They noted that the lack of good-quality evidence in early studies, which were often small and flawed, made it impossible to draw any definitive conclusions on efficacy or safety.¹¹
The National Institutes of Health (NIH): The NIH’s official COVID-19 Treatment Guidelines Panel recommends against the use of ivermectin for the treatment of COVID-19 outside of a clinical trial.¹² This recommendation is based on the consistent negative results from recent well-conducted clinical trials.
The World Health Organization (WHO): In 2021, the WHO issued a statement advising against the use of ivermectin for COVID-19 patients, “except within clinical trials.”¹³ Their position was based on the “very low certainty” of evidence from available trial data at the time.

Conclusion

While ivermectin is a safe and effective drug for its intended purpose of treating parasitic infections in humans and animals, the scientific community has reached a firm conclusion regarding its use for COVID-19. The vast body of reliable evidence from large-scale, rigorous clinical trials demonstrates that it provides no significant clinical benefit in reducing the risk of hospitalization, death, or disease progression.

The discrepancy between early, promising laboratory findings and the later disappointing clinical trial results highlights the importance of basing medical decisions on robust, peer-reviewed evidence. The public promotion of ivermectin for an unproven use created a dangerous situation, as it led to an increase in calls to poison control centers from people taking improperly dosed animal formulations of the drug.¹⁴

The consensus from leading global health organizations and the scientific community is clear: ivermectin is not an effective treatment for COVID-19 and should not be used for that purpose.¹⁵

SOURCES:

PubMed Central
pmc.ncbi.nlm.nih.gov
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines – PMC
Developing new medications can take years; therefore, identifying existing drugs that can be repurposed against COVID-19 that already have an established …

PubMed Central
pmc.ncbi.nlm.nih.gov
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19 – PMC
With regard to investigations into potential drug treatments against COVID-19, ivermectin has received particular attention. Indeed, a number of clinical …

PubMed Central
pmc.ncbi.nlm.nih.gov
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial – PubMed Central
In March 2020, Australian researchers demonstrated that ivermectin, a drug used for decades to combat parasitic infections, had antiviral activity against …

The Medical Letter
secure.medicalletter.org
COVID-19 Update: NIH Recommends Against Ivermectin | The Medical Letter Inc.
In vitro, high concentrations of ivermectin inhibit SARS-CoV-2 replication,2 but achieving comparable concentrations of the drug in lung tissue or plasma would …

Oxford Academic – Oxford University Press
academic.oup.com
Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud – Oxford Academic
Abstract. Ivermectin has become a controversial potential medicine for coronavirus disease 2019. Some early studies suggested clinical benefits in treatment of …

News-Medical
http://www.news-medical.net
Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection – News-Medical
This caused an explosion of interest, with some groups lobbying for it to be used worldwide. Shortly after, several of these studies were shown to be …

Nuffield Department of Primary Care Health Sciences – University of Oxford
http://www.phc.ox.ac.uk
New study shows ivermectin lacks meaningful benefits in COVID-19 treatment
Moreover, and importantly for both patients and reducing the burden on healthcare systems, ivermectin did not reduce the risk of COVID-19-related …

PRINCIPLE Trial
http://www.principletrial.org
New study shows ivermectin lacks meaningful benefits in COVID-19 treatment
While a modest two-day reduction in symptom duration, from 16 days to 14 days, was observed, this did not translate into clinically meaningful benefits or …

Cochrane
http://www.cochrane.org
Ivermectin for preventing and treating COVID-19 – Cochrane
Ivermectin for preventing and treating COVID-19 – We found no evidence to support the use of ivermectin for treating COVID‐19 or preventing SARS‐CoV‐2 …

The Medical Letter
secure.medicalletter.org
COVID-19 Update: NIH Recommends Against Ivermectin | The Medical Letter Inc.
Select a term to see related articles bebtelovimab COVID-19 ivermectin Lagevrio molnupiravir nirmatrelvir Paxlovid remdesivir Ritonavir Veklury. On April 29, …

World Health Organization (WHO)
http://www.who.int
WHO advises that ivermectin only be used to treat COVID-19 within clinical trials
The current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive. Until more data is available, WHO recommends that the drug only be …

American Medical Association
http://www.ama-assn.org
Why ivermectin should not be used to prevent or treat COVID-19
This growing interest in ivermectin to treat humans with COVID-19 has led to an increase in calls to poison control reporting overdoses and adverse effects.

University of Kansas Medical Center
http://www.kumc.edu
Ivermectin shown ineffective in treating COVID-19, according to multi-site study including KU Medical Center
“The most important takeaway from the study is that ivermectin does not help improve outcomes from COVID-19 infection and thus should not be used as a …